Objectives: Globally there is an increased prevalence of carbapenem-resistant Acinetobacter spp. (CRAs) and carbapenemase-producing Acinetobacter spp. (CPAs) in the hospital setting. This increase prompted the Canadian Nosocomial Infection Surveillance Program (CNISP) to conduct surveillance of CRA colonizations and infections identified from patients in CNISP-participating hospitals between 2010 and 2016.
Introduction
Acinetobacter baumannii has emerged as an important healthcareassociated pathogen due to its ability to rapidly develop antibiotic resistance, intra-and inter-hospital outbreak spread and international clonal dissemination. 1, 2 The acquisition of carbapenem resistance in Acinetobacter is most often due to carbapenem-hydrolysing class D b-lactamases (CHDLs) predominantly from the OXA-23, OXA-24/40, OXA-58, OXA-143 and OXA-235 groups. [1] [2] [3] [4] This report describes the incidence, epidemiology and molecular mechanisms of carbapenem-resistant Acinetobacter spp. (CRAs) collected over 7 years (2010-16) from a national hospital surveillance network, the Canadian Nosocomial Infection Surveillance Program (CNISP).
Methods
Description of the surveillance study and BC, British Columbia). The first Acinetobacter sp. collected from a patient during a single admission was considered eligible for inclusion and sent to the National Microbiology Laboratory (NML) for further analysis. A questionnaire was completed for all patients, which provided detailed patient history regarding travel, underlying medical conditions and patient outcome. Annual incidence rates for CRA from inpatients were calculated per 1000 admissions and 10 000 patient days. Incidence rates were compared using the z-test or Fisher's exact test as appropriate. Linear regression was used to identify significant changes in incidence rates over time.
Bacterial identification and antimicrobial susceptibility testing
Bacteria were initially identified at the submitting hospital with confirmation done at the NML using the taxonomic sequence classifier Kraken 5 and using OrthoANI. 6 Antimicrobial susceptibilities were determined using VITEK 2 AST-N219 cards and Etest strips (bioMérieux, St Laurent, Canada) or broth microdilution (colistin) using CLSI or FDA (tigecycline) breakpoints. XDR isolates were defined based on the recently published Canadian recommendations of full resistance to ciprofloxacin, piperacillin/tazobactam, ceftazidime, tobramycin and imipenem or meropenem. 7 
WGS and bioinformatic analyses
All 94 eligible isolates in this study were subjected to WGS on the MiSeq TM platform (Illumina, San Diego, CA, USA). Assembled reads (contigs) were analysed using tools at the Centre for Genomic Epidemiology website (https://cge.cbs.dtu.dk/services/). Single nucleotide variant (SNV) analysis was conducted using the SNVPhyl pipeline. 8 A. baumannii TYTH-1 (accession number CP003856) and A. baumannii K1-12-008 pseudogenomes were used as reference genomes in the SNV analyses.
GenBank accession numbers
All WGS read data were uploaded to the Sequence Read Archive of NCBI under the BioProject PRJNA390934. The bla OXA-565 gene was assigned the accession number KY883665 and the ampC genes from Acinetobacter bereziniae K1-16-076 and Acinetobacter soli K1-13-056 were assigned the accession numbers MG987619 and MG987620, respectively.
Results and discussion
Acinetobacter species and epidemiological data for CRA cases A total of 94 CRA isolates were collected: 90 A. baumannii, 2 Acinetobacter pittii, 1 A. bereziniae and 1 A. soli. The 94 CRAs were isolated in 2010 (n " 9), 2011 (n " 2), 2012 (n " 10), 2013 (n " 38), 2014 (n " 8), 2015 (n " 9) and 2016 (n " 18) from either western (22.3%) or central (77.7%) regions. From 2010 to 2016 the overall incidence rates for CRA were 0.02 per 10 000 patient days and 0.015 per 1000 admissions and did not significantly increase over the 7 years of surveillance (P . 0.73). Table S1 (available as Supplementary data at JAC Online) summarizes the demographic data available for patients. Data on international travel was available for 85 (90.4%) cases, of whom 33 (38.8%) had reported international travel in the past 12 months, with 31 of those having received medical treatment abroad. Thirty day outcome data were available for all 41 infected CRA cases, with 10 deaths reported. All-cause mortality 30 days from the date of positive culture was 24.4%. In all but two deaths the patient had an underlying medical condition.
MLST STs
All A. baumannii and A. pittii were typed in silico from the WGS data using both the Oxford (OX) and Pasteur (PA) MLST schemes. There were 30 different STs using the OX scheme and 17 using the PA scheme. The majority of isolates (79.8%, n " 75) belonged to the international clonal group 2 (IC2) 2 with most of those (n " 70) being ST2 PA . The ST2 PA isolates represented 12 OX STs, with 71.4% being ST208 OX . STs are shown in Figure 1 .
Antimicrobial susceptibilities and non-b-lactamase resistance genes
A summary of antimicrobial data is found in Table S2 and nonb-lactamase content is shown in Table S3 . CRAs were commonly resistant to ciprofloxacin (95.7%), trimethoprim/sulfamethoxazole (89.4%) gentamicin (80.9%) and tobramycin (77.6%). Resistance to tigecycline (5.3%, n " 5) and colistin (4.3%, n " 4) was rare. Mutations in GyrA (Ser83Leu) and ParC (Ser80Leu) known to be associated with quinolone resistance were detected in 95.6% of ciprofloxacin-resistant isolates. 9, 10 Colistin resistance in clinical Acinetobacter spp. is most often due to mutations in the pmrA or pmrB genes or the lpxA, lpxC or lpxD genes. [11] [12] [13] [14] [15] All four of the colistin-resistant isolates had amino acid changes in PmrB as compared with the control strains and one isolate, I1-16-001, had an M103K change in LpxC as well (Table S4 ). The two isolates with the highest MICs (.16 mg/L) had two amino acid changes in PmrB. The mobile colistin resistance genes mcr-1 to mcr-5 were not detected. According to recent Canadian guidelines, 10 78.7% (74/94) of isolates in this study would be classified as XDR. 14 
b-Lactamase gene content
The b-lactamase content (except for intrinsic class C) of all 94 isolates is listed in Table S5 and the number of CHDLs by year is shown in Figure S1 . An acquired OXA-type carbapenemase was found in 93 of the isolates with most harbouring an OXA-235-group 4 (48.4%, n " 45) or OXA-23-group (41.9%, n " 39) enzyme. One A. baumannii also harboured NDM-1 and one A. pittii also harboured IMP-26. All isolates except the A. soli harboured an intrinsic class D gene with ISAba1 located upstream in a single isolate, the one CRA without an acquired CHDL (Figure 2 ). All A. baumannii and A. pittii isolates except one harboured an Boyd et al.
intrinsic class C bla ADC -group gene with 88.3% (n " 83) of them being preceded by an ISAba1 element. Intrinsic class C ampC genes were also found in A. bereziniae K1-16-076 (accession number MG987619) and A. soli K1-13-056 (accession number MG987620), but they exhibited only a distant relationship (46%-53% identity) to the bla ADC group.
SNV analysis
SNV analysis of the core genome was conducted on all A. baumannii and A. pittii isolates (n " 92) to determine broad phylogenetic relatedness (Figure 1 ). There were four broad clusters: the A. pittii cluster (n " 2); a diverse cluster of 15 isolates including the IC1 Figure 1 . Phylogenetic tree based on SNV differences of the A. baumannii and A. pittii isolates in this study (n " 92). In this analysis 57.2% of the core genome and 12 860 SNV sites were used to determine the phylogeny. Tips are labelled with the ST (PA scheme/OX scheme) and the acquired carbapenemase gene(s) they harbour or a circle indicating OXA-23. The location where the bacterium was isolated is indicated by a square for central Canada or a triangle for western Canada. The gap in the A. pittii branch represents 88% reduction of the actual branch length. One OXA-237-harbouring isolate was ST1024 OX , a single locus variant (gpi) of ST208 OX . The reference genome used in the analysis was A. baumannii TYTH-1 (accession number CP003856) and the isolate it was most closely related to is indicated by an asterisk.
Carbapenemase-producing Acinetobacter baumannii in Canada JAC isolates; the IC2 cluster of 70 isolates mainly consisting of ST2 PA isolates; and a cluster of five isolates consisting of four ST557 PA / 796 OX and one ST215 PA /1499 OX . To obtain a finer resolution of the ST2 PA isolates we conducted SNV analysis of only these 70 isolates (Figure 2 ). Overall the 70 isolates differ by 0-3234 SNVs in this analysis; however, the majority (n " 61) differ by ,500 SNVs and could be divided into five subclusters of .2 isolates including the OXA-235 and OXA-237 clusters. All nine OXA-235-harbouring isolates were collected from patients in the ICU of one hospital over a five month period in 2016. All of the isolates were epidemiologically linked to the index case who had recently received medical care in the USA and thus these cases constitute a small outbreak. All 36 OXA-237-harbouring isolates were collected in a different hospital in 2012 (n " 4), 2013 (n " 29) and 2014 (n " 3), with only one case (of 34) with reported international travel. A detailed analysis of possible transmission routes of these isolates in the hospital is the subject of another study (C. Bogaty, L. Mataseje, A. Grey, B. Lefebvre, S. Levesque, M. Mulvey and Y. Longtin, unpublished data). The A. baumannii plasmid pORAB01-3 harbouring OXA-237 was previously found in 16 isolates collected from June 2012 to October 2014 in the state of Oregon. 16, 17 We did find the pORAB01-3 backbone (12 kb) in the assemblies of the OXA-237 isolates in this study; however, due to the limitations of short-read sequencing this could not be linked to bla .
Conclusions
This study indicates that rates of CRA have not significantly increased over 7 years of CNISP surveillance and rates remain low as previously reported. 18, 19 A limitation of this study is that Figure 2 . Phylogenetic tree based on SNV differences of the ST2 PA A. baumannii in this study (n " 70). In this analysis 85.5% of the core genome and 6498 SNV sites were used to determine phylogeny. Tips are labelled with the isolate number and the ST OX number. xx(x)-xx-xxx " hospital site-year of isolation (e.g. 16"2016)-individual isolate. The location where the bacterium was isolated is as in Figure 1 . A. baumannii K1-13-028 did not harbour an acquired CHDL, but had ISAba1 upstream of its intrinsic OXA-82 (OXA-51 group) gene. The reference genome used in the analysis was the A. baumannii K1-12-008 pseudogenome.
data on previous hospital admission or CRA status were not collected and hence multiple isolates for the same patient may be included in our analysis. Our surveillance data indicate that 38.8% of patients reported travel outside of Canada within the past 12 months and, with the exception of two patients, all received medical treatment while travelling. This suggests that travel and receipt of medical care outside of Canada are important factors in the importation of CPA into Canada though no region of travel predominated. The most prevalent strain type identified in every year of this surveillance period was A. baumannii ST2 PA harbouring OXA-23 (n " 38). This is in agreement with reports of IC2 A. baumannii harbouring OXA-23 being the most globally spread CRA. 1, 2 In this study 78.7% of isolates were XDR underscoring the prevalence of this feature in healthcare-associated Acinetobacter spp. More concerning was the finding that four of the XDR isolates were also resistant to colistin with two of those intermediately resistant to tigecycline, thus further limiting treatment options. The high association with XDR and putative outbreak isolates warrants the continued surveillance of this organism.
